نتایج جستجو برای: tki

تعداد نتایج: 3304  

2016
Rhiannon N. Hardwick Marina Snellings Brian C. Ferslew Yang Lu Kim L.R. Brouwer

Tyrosine and aurora kinases are important effectors in signal transduction pathways that are often involved in aberrant cancer cell growth. Tyrosine (TKI) and aurora (AKI) kinase inhibitors are anti-cancer agents specifically designed to target such signaling pathways through TKI/AKI binding to the ATP-binding pocket of kinases thereby leading to diminished kinase activity. Some TKIs have been ...

2017
Fam Xeng Inn Nurzarina Ahmed Erica Yee Hing Mohd Hafidzul Jasman

Tyrosine kinase inhibitor (TKI) and its side effects are well known. However, these are mainly descriptive, with pictorial data lacking. Here, in we report a case of metastatic renal cell carcinoma, treated with TKI, with classic side effects; supplemented with images that demonstrate the adverse effects of the drug. In addition, we discuss and demonstrate the computed tomography changes.

Journal: :Indian journal of physiology and pharmacology 2022

Objectives: This study compares the adverse effects (AEs) associated with trastuzumab in treatment of human epidermal growth factor receptor 2-positive breast cancer ( HER-2 + BC) when used alone or combination chemotherapy tyrosine kinase inhibitors, so as to aid rational choices. Materials and Methods: An electronic search was conducted on PubMed using Mesh terms ‘BC’, ‘HER-2 positive’, ‘meta...

Journal: :Oncotarget 2015
Mary E Irwin Blake P Johnson Roxsan Manshouri Hesham M Amin Joya Chandra

Tyrosine kinase inhibitors (TKI) have improved CML response rates, and some are effective against resistance-promoting point mutations in BCR-ABL1. However, in the absence of point mutations, resistance still occurs. Here, we identify a novel pathway mediating resistance which connects p47phox, the organizer subunit of NADPH oxidase-2 (NOX2), with early growth response-1 (Egr-1) and the Src fam...

2017
Ling Li Xiajing Gu Jinnan Yue Qingnan Zhao Dacheng Lv Hongzhuan Chen Lu Xu

Epithelial-mesenchymal transition (EMT) is clinically associated with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in non-small cell lung cancers (NSCLC). However, the mechanisms promoting EMT in EGFR TKI-resistant NSCLC have not been fully elucidated. Previous studies have suggested that IGF1R signaling is involved in both acquired EGFR TKI re...

2017
Hiroki Sato Kazuhiko Shien Shuta Tomida Kazuhiro Okayasu Ken Suzawa Shinsuke Hashida Hidejiro Torigoe Mototsugu Watanabe Hiromasa Yamamoto Junichi Soh Hiroaki Asano Kazunori Tsukuda Shinichiro Miyoshi Shinichi Toyooka

MicroRNA (miR)-200 family members (miR-200s) are frequently silenced in advanced cancer and have been implicated in the process of epithelial-to-mesenchymal transition (EMT). We previously reported that miR-200s were silenced through promoter methylation in acquired EGFR-tyrosine kinase inhibitor (TKI) resistant non-small cell lung cancer (NSCLC) cells harboring EMT features. In this study, we ...

2011
Maeva Dufies Arnaud Jacquel Nathalie Belhacene Guillaume Robert Thomas Cluzeau Fréderic Luciano Jill Patrice Cassuto Sophie Raynaud Patrick Auberger

AXL is a receptor tyrosine kinase of the TAM family, the function of which is poorly understood. We previously identified AXL overexpression in Imatinib (IM)-resistant CML cell lines and patients. The present study was conducted to investigate the role of AXL and the mechanisms underlying AXL overexpression in Tyrosine Kinase Inhibitor (TKI)-resistant CML cells. We present evidence that high AX...

Journal: :Molecular cancer therapeutics 2013
Warren Fiskus Srdan Verstovsek Taghi Manshouri Jacqueline E Smith Karissa Peth Sunil Abhyankar Joseph McGuirk Kapil N Bhalla

Hemopoietic progenitor cells (HPC) from myeloproliferative neoplasms (MPN) such as myelofibrosis commonly express mutant JAK2-V617F or other mutations that are associated with increased activities of JAK-STAT5/3, RAS/RAF/MAPK, and PI3K/AKT/mTOR pathways. This confers proliferative and survival advantage on the MPN HPCs. Treatment with JAK tyrosine kinase inhibitor (TKI), for example, TG101209, ...

Journal: :JCI insight 2016
Jesús García-Donas Benoit Beuselinck Lucía Inglada-Pérez Osvaldo Graña Patrick Schöffski Agnieszka Wozniak Oliver Bechter Maria Apellániz-Ruiz Luis Javier Leandro-García Emilio Esteban Daniel E Castellano Aranzazu González Del Alba Miguel Angel Climent Susana Hernando José Angel Arranz Manuel Morente David G Pisano Mercedes Robledo Cristina Rodriguez-Antona

The majority of metastatic renal cell carcinoma (RCC) patients are treated with tyrosine kinase inhibitors (TKI) in first-line treatment; however, a fraction are refractory to these antiangiogenic drugs. MicroRNAs (miRNAs) are regulatory molecules proven to be accurate biomarkers in cancer. Here, we identified miRNAs predictive of progressive disease under TKI treatment through deep sequencing ...

2015
Yi-Nan Liu Tzu-Hua Chang Meng-Feng Tsai Shang-Gin Wu Tzu-Hsiu Tsai Hsuan-Yu Chen Sung-Liang Yu James Chih-Hsin Yang Jin-Yuan Shih

Epidermal growth factor receptor (EGFR)-targeted strategy is limited by resistance. We identify the potential genes involved in EGFR TKI (tyrosine kinase inhibitor) resistance and study the therapeutic mechanism in the non-small cell lung cancers. Potential genes involved in resistance were examined by analyzing datasets from a pair of EGFR TKI-sensitive (PC9) and TKI-resistant cells (PC9/gef)....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید